PURPOSE: Clinically evident chronic pancreatitis is a strong risk factor for pancreatic cancer. A small Japanese cohort study previously reported that pre-diagnostic serum transforming growth factor-β1 (TGF-β1) concentration, a potential marker of subclinical pancreatic inflammation, was associated with higher risk of pancreatic cancer. We further explored this association in a larger prospective study. METHODS: Serum TGF-β1 concentrations were measured in pre-diagnostic samples from 729 pancreatic cancer cases and 907 matched controls from a cohort of Finnish male smokers (the Alpa-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study) and two cohorts of US men and women, the Cancer Prevention Study-II and the Prostate Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Multivariable-adjusted odds ratios (ORs) were estimated using conditional logistic regression. RESULTS: Overall, serum TGF-β1 concentration was not associated with a clear increase in pancreatic cancer risk (OR 1.36, 95 % confidence interval (CI) 0.98-1.88 for highest vs. lowest quintile, p trend = 0.20). However, this association differed significantly by follow-up time (p = 0.02). Serum TGF-β1 concentration was not associated with risk during the first 10 years of follow-up, but was associated with higher risk during follow-up after 10 years (OR 2.13, 95 % CI 1.23-3.68 for highest vs. lowest quintile, p trend = 0.001). During follow-up after 10 years, serum TGF-β1 was associated with higher risk only in the ATBC cohort, although most subjects were from ATBC during this time period and statistical evidence for heterogeneity across cohorts was limited (p = 0.14). CONCLUSIONS: These results suggest that high serum TGF-β1 may be associated with increased risk of pancreatic cancer although a long follow-up period may be needed to observe this association.
PURPOSE: Clinically evident chronic pancreatitis is a strong risk factor for pancreatic cancer. A small Japanese cohort study previously reported that pre-diagnostic serum transforming growth factor-β1 (TGF-β1) concentration, a potential marker of subclinical pancreatic inflammation, was associated with higher risk of pancreatic cancer. We further explored this association in a larger prospective study. METHODS: Serum TGF-β1 concentrations were measured in pre-diagnostic samples from 729 pancreatic cancer cases and 907 matched controls from a cohort of Finnish male smokers (the Alpa-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study) and two cohorts of US men and women, the Cancer Prevention Study-II and the Prostate Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Multivariable-adjusted odds ratios (ORs) were estimated using conditional logistic regression. RESULTS: Overall, serum TGF-β1 concentration was not associated with a clear increase in pancreatic cancer risk (OR 1.36, 95 % confidence interval (CI) 0.98-1.88 for highest vs. lowest quintile, p trend = 0.20). However, this association differed significantly by follow-up time (p = 0.02). Serum TGF-β1 concentration was not associated with risk during the first 10 years of follow-up, but was associated with higher risk during follow-up after 10 years (OR 2.13, 95 % CI 1.23-3.68 for highest vs. lowest quintile, p trend = 0.001). During follow-up after 10 years, serum TGF-β1 was associated with higher risk only in the ATBC cohort, although most subjects were from ATBC during this time period and statistical evidence for heterogeneity across cohorts was limited (p = 0.14). CONCLUSIONS: These results suggest that high serum TGF-β1 may be associated with increased risk of pancreatic cancer although a long follow-up period may be needed to observe this association.
Authors: Jason B Douglas; Debra T Silverman; Stephanie J Weinstein; Barry I Graubard; Michael N Pollak; Yuzhen Tao; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-12-20 Impact factor: 4.254
Authors: T R Fears; R G Ziegler; J L Donaldson; R T Falk; R N Hoover; F Z Stanczyk; J B Vaught; M H Gail Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-04 Impact factor: 4.254
Authors: Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun Journal: Cancer Date: 2002-05-01 Impact factor: 6.860
Authors: Ying Bao; Edward L Giovannucci; Peter Kraft; Zhi Rong Qian; Chen Wu; Shuji Ogino; J Michael Gaziano; Meir J Stampfer; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Michael N Pollak; Li Jiao; Lawrence Lessin; Barbara B Cochrane; Joann E Manson; Charles S Fuchs; Brian M Wolpin Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-05 Impact factor: 4.254
Authors: L M Wakefield; J J Letterio; T Chen; D Danielpour; R S Allison; L H Pai; A M Denicoff; M H Noone; K H Cowan; J A O'Shaughnessy Journal: Clin Cancer Res Date: 1995-01 Impact factor: 12.531
Authors: Rachael Z Stolzenberg-Solomon; Christina C Newton; Debra T Silverman; Michael Pollak; Leticia M Nogueira; Stephanie J Weinstein; Demetrius Albanes; Satu Männistö; Eric J Jacobs Journal: Am J Epidemiol Date: 2015-06-17 Impact factor: 4.897
Authors: Nitin Shivappa; Cristina Bosetti; Antonella Zucchetto; Diego Serraino; Carlo La Vecchia; James R Hébert Journal: Br J Nutr Date: 2014-12-17 Impact factor: 3.718
Authors: A K Thakur; J Nigri; S Lac; J Leca; C Bressy; P Berthezene; L Bartholin; P Chan; E Calvo; J L Iovanna; S Vasseur; F Guillaumond; R Tomasini Journal: Cell Death Differ Date: 2016-03-04 Impact factor: 15.828
Authors: Stephanie H Greco; Lena Tomkötter; Anne-Kristin Vahle; Rae Rokosh; Antonina Avanzi; Syed Kashif Mahmood; Michael Deutsch; Sara Alothman; Dalia Alqunaibit; Atsuo Ochi; Constantinos Zambirinis; Tasnima Mohaimin; Mauricio Rendon; Elliot Levie; Mridul Pansari; Alejandro Torres-Hernandez; Donnele Daley; Rocky Barilla; H Leon Pachter; Daniel Tippens; Hassan Malik; Allal Boutajangout; Thomas Wisniewski; George Miller Journal: PLoS One Date: 2015-07-14 Impact factor: 3.240